Evolent Health, Inc. (NYSE:EVH) Receives $25.90 Average PT from Brokerages

Evolent Health, Inc. (NYSE:EVH) has been assigned a consensus rating of “Buy” from the twelve analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $26.18.

EVH has been the topic of a number of recent analyst reports. Barclays lowered their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Oppenheimer lowered their target price on shares of Evolent Health from $34.00 to $28.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $38.00 to $16.00 in a research report on Friday, November 8th. Royal Bank of Canada restated an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a research note on Tuesday, November 12th. Finally, BTIG Research decreased their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday.

Evolent Health Trading Down 7.9 %

Shares of NYSE EVH opened at $11.71 on Friday. The business has a fifty day moving average price of $21.12 and a 200 day moving average price of $23.26. Evolent Health has a 1-year low of $11.17 and a 1-year high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The stock has a market capitalization of $1.36 billion, a P/E ratio of -12.87 and a beta of 1.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co grew its position in shares of Evolent Health by 8.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 39,522 shares of the technology company’s stock valued at $1,297,000 after purchasing an additional 3,064 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Evolent Health by 11.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company’s stock worth $23,522,000 after acquiring an additional 75,376 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Evolent Health by 393.6% in the second quarter. Harbor Capital Advisors Inc. now owns 176,021 shares of the technology company’s stock worth $3,366,000 after acquiring an additional 140,357 shares during the last quarter. Valeo Financial Advisors LLC purchased a new stake in shares of Evolent Health during the second quarter worth approximately $2,705,000. Finally, Salem Investment Counselors Inc. raised its stake in Evolent Health by 88.1% in the 2nd quarter. Salem Investment Counselors Inc. now owns 225,901 shares of the technology company’s stock valued at $4,319,000 after purchasing an additional 105,780 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.